QIAGEN Launches QIAseq xHYB Long-Read Panels to Improve Genomic Research

QIAGEN Enhances its Portfolio with Long-read Panels

Announcement

Qiagen has introduced new QIAseq xHYB long-read panels, a groundbreaking solution designed to explore the long-read sequencing of genomically complex regions. This sequencing idea strongly builds Qiagen’s position as a provider of as many brilliant solutions for next-generation sequencing (NGS) platforms that stretch across long and short read technologies. The new Qiagen panels are enhanced to integrate with native long-read platforms, consisting of PacBio (NASDAQ:  PACB). The idea has been taken into consideration to provide researchers pinpoint the vast spectrum of genomic variation. The applications, such as HLA typing, detection of structural variants, and continued expansion analysis, are applications in which short-read sequencing reflects hurdles.

How Effective are QIAseq xHYB Long-read Panels?

Based on QIAGEN’s hybrid capture chemistry, the QIAseq xHYB long-read panels provide compatibility with increased molecular weight DNA extraction kits and set a high target of uniformity and completeness. Apart from this, the long read panels include flexible formats consisting of HLA typing, fixed panels for hereditary cancers, also customized panels. The effortless combination with QIAGEN digital insights bioinformatics streamlines the data process and smoothens it.

Enhancement to QIAGEN’s portfolio

With the launch of new long sequencing, clinical and translational research has been eased in complex regions. The native long read sequencing enables excellent insight into intricate genomic regions, which is a highlight due to its precision in haplotype phasing, variant resolution, and multiple times detection. This is more prominent in comparison to synthetic long or short read technologies. The expansion and enhancement are a huge support to researchers as they now have an option to choose between long and short read sequencing, or either merge them according to their research objectives and sample type.

Views and Statements

Senior vice president and head of product portfolio and innovation at QIAGEN, Nitin Sood, said, “This new platform is a milestone in our genomics strategy, and it also mirrors our commitment to serve solid science. This is an investment in our portfolio in support of our existing NGS applications. It will help us expand across certain boundaries of possibilities, such as cancer biology, immune profiling, and intricated diseases.”

Vice president, global marketing at PacBio, David Miller said, “We are thrilled to extend our sequencing offering under the partnership with QIAGEN. With this new idea, we see the acceptance of our remarkable sequencer, Vega, which accelerates the power of HiFi sequencing. HiFi is welcoming new possibilities in most focused sequencing, mainly in translational and clinical research applications.”